• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    National Research Q1 EPS $0.28 Down From $0.34 YoY, Sales $36.47M Down From $38.44M YoY

    5/2/23 5:00:52 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NRC alert in real time by email
    National Research (NASDAQ:NRC) reported quarterly earnings of $0.28 per share. This is a 17.65 percent decrease over earnings of $0.34 per share from the same period last year. The company reported $36.47 million in sales this quarter. This is a 5.12 percent decrease over sales of $38.44 million the same period last year.
    Get the next $NRC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Financial Officer Harrison Shane R bought $98,162 worth of shares (8,000 units at $12.27) (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    2/19/26 5:02:50 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Lockhart Stephen H

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    2/17/26 7:21:50 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Bhandari Parul

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    2/17/26 7:19:51 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    SEC Filings

    View All

    SEC Form S-8 filed by National Research Corporation

    S-8 - NATIONAL RESEARCH CORP (0000070487) (Filer)

    3/5/26 12:47:06 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-K filed by National Research Corporation

    10-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

    3/5/26 9:57:16 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 424B7 filed by National Research Corporation

    424B7 - NATIONAL RESEARCH CORP (0000070487) (Filer)

    2/10/26 5:06:26 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRC Health Provides Business Update

    TRCV surpasses $152 million, increasing 6% from the end of 2025 and 13% year-over-year National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced that it has surpassed $152 million in Total Recurring Contract Value (TRCV) as of March 4, 2026, representing an all-time high in the metric for NRC Health. TRCV represents the amount of revenue projected to be recognized over the next 12 months from renewable contracts and is calculated consistent with the definition previously disclosed in the company's periodic reports filed with the Securities and Exchange Commission. "This TRCV milestone reflects the confidence o

    3/4/26 4:15:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Named #1 Best in KLAS Again for Healthcare Experience Management

    NRC Health, a leader in healthcare-built technology and data-driven insights advancing Human Understanding in care delivery, today announced it has received the 2026 Best in KLAS Award for Healthcare Experience Management for the third time in four years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204821939/en/ This honor highlights NRC Health's long-standing leadership in healthcare experience management, built on more than 40 years of innovation and collaboration. "This recognition reflects the dedication of our team and the trust our partners place in us," said Trent Green, CEO of NRC Health. "For more than four deca

    2/4/26 8:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Fourth Quarter 2025 Results

    Fourth quarter TRCV* increased 8% year-over-year to $144.1 million Cash flow from operations increased 13% year-over-year to $7.2 million National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced results for the fourth quarter 2025. "Our fourth quarter results reflect the strong, disciplined execution happening across NRC Health and the deep trust our customers place in us," said Trent Green, CEO of NRC Health. "With TRCV reaching $144 million and momentum building across our portfolio, we finished the year with a strong foundation for continued execution. As healthcare leaders navigate unprecedented complexit

    2/3/26 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Financial Officer Harrison Shane R bought $98,162 worth of shares (8,000 units at $12.27) (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    2/19/26 5:02:50 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Accounting Officer Freeman Jordan Nicole bought $10,000 worth of shares (771 units at $12.97) (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    8/4/25 4:40:44 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    5/13/25 11:30:22 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Leadership Updates

    Live Leadership Updates

    View All

    NRC Health Appoints David Burik as Executive Vice President, Strategic Insights

    Seasoned healthcare strategy leader to advance The Governance Institute and Market Insights NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120531393/en/NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. David joins NRC Health from Guidehouse, where he has served as partner and leader of the Center for Health Insigh

    11/20/25 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Shane Harrison as Chief Financial Officer

    National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare experience, is pleased to announce the appointment of Shane Harrison as its incoming Executive Vice President and Chief Financial Officer, effective on or about September 25, 2025. Chief Financial Officer Shane Harrison is a seasoned finance leader with more than 25 years of experience spanning corporate finance, investor relations, and strategic transactions. He most recently served as Senior Vice President – Finance and Investor Relations at PowerSchool, a leading K-12 education SaaS provider, since 2022. Prior to that, he served as Senior Vice President – Corporate Develop

    8/28/25 8:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    National Research Corporation Appoints Trent Green as Chief Executive Officer

    National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare improvement, is pleased to announce the appointment of Trent Green as its incoming Chief Executive Officer, effective June 1, 2025. Green will succeed Mike Hays, the company's current CEO, who will transition to the role of Chairman, ensuring a smooth leadership transition while maintaining NRC Health's mission-driven and shareholder-focused approach. Green brings more than 25 years of healthcare leadership experience, most recently serving as CEO of One Medical, San Francisco, CA, and previously as Chief Operating Officer at Legacy Health, Portland, OR. His expertise in care de

    3/4/25 4:01:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Financials

    Live finance-specific insights

    View All

    NRC Health Provides Business Update

    TRCV surpasses $152 million, increasing 6% from the end of 2025 and 13% year-over-year National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced that it has surpassed $152 million in Total Recurring Contract Value (TRCV) as of March 4, 2026, representing an all-time high in the metric for NRC Health. TRCV represents the amount of revenue projected to be recognized over the next 12 months from renewable contracts and is calculated consistent with the definition previously disclosed in the company's periodic reports filed with the Securities and Exchange Commission. "This TRCV milestone reflects the confidence o

    3/4/26 4:15:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Fourth Quarter 2025 Results

    Fourth quarter TRCV* increased 8% year-over-year to $144.1 million Cash flow from operations increased 13% year-over-year to $7.2 million National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced results for the fourth quarter 2025. "Our fourth quarter results reflect the strong, disciplined execution happening across NRC Health and the deep trust our customers place in us," said Trent Green, CEO of NRC Health. "With TRCV reaching $144 million and momentum building across our portfolio, we finished the year with a strong foundation for continued execution. As healthcare leaders navigate unprecedented complexit

    2/3/26 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Third Quarter 2025 Results

     Third quarter TRCV* increased 8% year-over-year to $141.7 million Cash flow from operations increased 46% year-over-year to $13.8 million National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced results for the third quarter 2025. "We delivered our fourth consecutive quarter of recurring contract value growth, driven by strong sales and meaningful improvement in customer retention," said Trent Green, CEO of NRC Health. "This sustained momentum reflects how our solutions deliver insights, engagement, and enablement that help healthcare organizations better understand, anticipate, and respond to the experience

    10/27/25 5:00:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by National Research Corporation

    SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    11/13/24 4:05:19 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by National Research Corporation (Amendment)

    SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    3/8/24 4:05:05 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by National Research Corporation (Amendment)

    SC 13D/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    3/5/24 4:31:31 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care